Clovis Oncology Inc (CLVS) 23.40 $CLVS Biotech
Post# of 273257
Posted On: 09/03/2016 9:09:31 AM
Clovis Oncology Inc (CLVS) 23.40 $CLVS
Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Arpita Dutt - Zacks Investment Research - Wed Aug 24, 1:09PM CDT
Acquisitions are back in focus in the biotech sector with Medivation (MDVN) agreeing to be acquired by Pfizer for $14 billion.
MDVN: 80.85 (-0.08), BIIB: 313.59 (+7.56), PTLA: 21.03 (+0.17), CLVS: 23.40 (-0.19), GILD: 76.89 (-0.53), ALXN: 123.67 (-1.96), REGN: 388.64 (-4.76)
Clovis (CLVS) Stock Up on FDA Priority Review for Rucaparib
Arpita Dutt - Zacks Investment Research - Wed Aug 24, 5:48AM CDT
The FDA will respond on the approval status of rucaparib by Feb 23, 2017.
CLVS: 23.40 (-0.19), ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02)
FDA Accepts Clovis Oncology's New Drug Application for Rucaparib for Priority Review for the Treatment of Advanced Mutant BRCA Ovarian Cancer
BusinessWire - Tue Aug 23, 1:30PM CDT
--FDA Grants Priority Review Status
CLVS: 23.40 (-0.19)
Can The Uptrend Continue for Clovis Oncology (CLVS)?
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 8:58AM CDT
Investors certainly have to be happy with Clovis Oncology, Inc. (CLVS) and its short term performance
CLVS: 23.40 (-0.19)
Clovis Oncology Announces Q2 2016 Operating Results and Corporate Update
BusinessWire - Mon Aug 08, 3:05PM CDT
--FDA decision on filing and determination of PDUFA date is anticipated in late August
CLVS: 23.40 (-0.19)
Commit To Buy Clovis Oncology At $10, Earn 25.6% Annualized Using Options
StockOptionsChannel.com - Mon Jun 20, 10:38AM CDT
Investors eyeing a purchase of Clovis Oncology Inc stock, but cautious about paying the going market price of $14.17/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract...
CLVS: 23.40 (-0.19)
How These Biotech's Stocks are Performing? - Clovis Oncology, Illumina, NewLink Genetics and Zafgen
PR Newswire - Thu Jun 09, 7:00AM CDT
Some of the biggest opportunities in the equities market are found in tumultuous industries such as Biotechnology. The segment continues to present a number of remarkable trades as well as potentially good investment that are waiting to be discovered. This morning ActiveWallSt.com features these four biotech stocks in its technical alerts service: Clovis Oncology Inc. (NASDAQ: CLVS), Illumina Inc. (NASDAQ: ILMN), NewLink Genetics Corp. (NASDAQ: NLNK), and Zafgen Inc. (NASDAQ: ZFGN). Learn more about these stocks and receive your complimentary trade alerts at:
ZFGN: 2.95 (-0.09), CLVS: 23.40 (-0.19), NLNK: 9.91 (-0.40), ILMN: 167.90 (-0.66)
Clovis Oncology Presents Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer and Pancreatic Cancer at 2016 ASCO Annual Meeting
BusinessWire - Mon Jun 06, 7:30AM CDT
Clovis Oncology (NASDAQ:CLVS) announced updated phase 2 results from Part 1 of the ongoing ARIEL2 study in patients with advanced ovarian cancer as well as the final results of the RUCAPANC study of rucaparib in pancreatic cancer at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Rucaparib is the Company's oral, potent, small molecule inhibitor of PARP1, PARP2 and PARP3 currently being developed for the treatment of ovarian cancer, specifically in patients with tumors with BRCA mutations and other DNA repair deficiencies beyond BRCA, including those with high genomic loss of heterozygosity (LOH) also known as "BRCA-like."
CLVS: 23.40 (-0.19)
Clovis Oncology Announces Data Presentations at 2016 ASCO Annual Meeting
BusinessWire - Thu May 19, 3:40PM CDT
--Rolling New Drug Application (NDA) submission for rucaparib for the treatment of patients with advanced ovarian cancer expected to complete during Q2 2016
CLVS: 23.40 (-0.19)
The Shuman Law Firm Investigates Clovis Oncology, Inc.
BusinessWire - Wed May 11, 12:38PM CDT
The Shuman Law Firm announces that it is investigating potential claims against certain officers and directors of Clovis Oncology, Inc. ("Clovis" or the "Company"
(Nasdaq: CLVS). Clovis is a Boulder, CO-based biopharmaceutical company that focuses on anti-cancer agents.
CLVS: 23.40 (-0.19)
Clovis reports 1Q loss
Automated Insights - Thu May 05, 4:48PM CDT
BOULDER, Colo. (AP) _ Clovis Oncology Inc. (CLVS) on Thursday reported a loss of $83.4 million in its first quarter.
CLVS: 23.40 (-0.19)
Clovis Oncology to Announce First Quarter 2016 Financial Results and Host Webcast Conference Call on May 5
BusinessWire - Tue Apr 26, 7:00AM CDT
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2016 financial results on Thursday, May 5, 2016, after the close of the U.S. financial markets. Clovis' senior management will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the company's results in greater detail.
CLVS: 23.40 (-0.19)
Market Exclusive Research Weekly Biotech Report
ACCESSWIRE - Mon Apr 18, 8:27AM CDT
NEW YORK, NY / ACCESSWIRE / April 18, 2016 / The week just gone gave us plenty to talk about in the biotech space, with two significant developments - one in oncology and one in a rare genetic growth disorder called acromegaly. Here's what happened, and how things played out as a result.
PGNX: 5.96 (-0.18), CLVS: 23.40 (-0.19), SRPT: 26.89 (+0.33), COLL: 8.98 (+0.15), CHMA: 2.51 (+0.05)
The Zacks Analyst Blog Highlights: Intercept, Clovis, AbbVie, Relypsa and Horizon Pharma
Zacks Equity Research - Zacks Investment Research - Thu Apr 14, 8:30AM CDT
The Zacks Analyst Blog Highlights: Intercept, Clovis, AbbVie, Relypsa and Horizon Pharma
CLVS: 23.40 (-0.19), RLYP: 31.98 (-0.01), HZNP: 17.84 (-0.78), ICPT: 150.74 (+3.92), ABBV: 64.12 (+0.09)
Biotech Stock Roundup: FDA Advisory Panels Say Yes to Intercept, No to Clovis
Arpita Dutt - Zacks Investment Research - Wed Apr 13, 9:02AM CDT
A couple of experimental drugs were reviewed by the FDA's advisory panels with a positive outcome for Intercept (ICPT) while Clovis (CLVS) faces a possible delay in gaining approval for its drug.
VRTX: 95.11 (+0.36), CLVS: 23.40 (-0.19), RLYP: 31.98 (-0.01), HZNP: 17.84 (-0.78), ALXN: 123.67 (-1.96), ICPT: 150.74 (+3.92), ABBV: 64.12 (+0.09)
Why Horizon Pharma, Och-Ziff Capital Management, and Clovis Oncology Slumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Tue Apr 12, 5:58PM CDT
Image: Och-Ziff. Tuesday was a strong day for the stock market, and the primary reason was positive movement in the energy markets. Crude oil prices rose almost $2 per barrel, moving above $42 and carrying a huge swath of energy stocks along with...
CLVS: 23.40 (-0.19), HZNP: 17.84 (-0.78), OZM: 3.87 (+0.04)
Clovis Oncology's Failure Is a Big Win for AstraZeneca
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 12, 5:41PM CDT
IMAGE SOURCE: FLICKR USER STOCKMONKEYS.COM. Following a disastrous drubbing by the Food and Drug Administration's key advisory committee, the future for Clovis Oncology 's once-promising non-small cell lung cancer drug rociletinib is up in the...
CLVS: 23.40 (-0.19), AZN: 33.31 (+0.71)
Clovis Oncology Provides Update on FDA Oncologic Drugs Advisory Committee Meeting to Review Rociletinib for Treatment of Advanced T790M-Positive Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer
BusinessWire - Tue Apr 12, 12:52PM CDT
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) met to discuss approval of the New Drug Application (NDA) for rociletinib, an investigational therapy for the treatment of patients with mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC) who have been previously treated with an EGFR-targeted therapy and have the T790M mutation.
CLVS: 23.40 (-0.19)
Trading of Clovis Oncology, Inc. Common Stock Halted
BusinessWire - Tue Apr 12, 6:04AM CDT
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that NASDAQ has halted trading of the Company's common stock. The U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) is meeting this morning to discuss the company's New Drug Application (NDA) for rociletinib for the treatment of patients with mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC) who have been previously treated with an EGFR-targeted therapy and have the EGFR T790M mutation.
CLVS: 23.40 (-0.19)
Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Arpita Dutt - Zacks Investment Research - Wed Aug 24, 1:09PM CDT
Acquisitions are back in focus in the biotech sector with Medivation (MDVN) agreeing to be acquired by Pfizer for $14 billion.
MDVN: 80.85 (-0.08), BIIB: 313.59 (+7.56), PTLA: 21.03 (+0.17), CLVS: 23.40 (-0.19), GILD: 76.89 (-0.53), ALXN: 123.67 (-1.96), REGN: 388.64 (-4.76)
Clovis (CLVS) Stock Up on FDA Priority Review for Rucaparib
Arpita Dutt - Zacks Investment Research - Wed Aug 24, 5:48AM CDT
The FDA will respond on the approval status of rucaparib by Feb 23, 2017.
CLVS: 23.40 (-0.19), ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02)
FDA Accepts Clovis Oncology's New Drug Application for Rucaparib for Priority Review for the Treatment of Advanced Mutant BRCA Ovarian Cancer
BusinessWire - Tue Aug 23, 1:30PM CDT
--FDA Grants Priority Review Status
CLVS: 23.40 (-0.19)
Can The Uptrend Continue for Clovis Oncology (CLVS)?
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 8:58AM CDT
Investors certainly have to be happy with Clovis Oncology, Inc. (CLVS) and its short term performance
CLVS: 23.40 (-0.19)
Clovis Oncology Announces Q2 2016 Operating Results and Corporate Update
BusinessWire - Mon Aug 08, 3:05PM CDT
--FDA decision on filing and determination of PDUFA date is anticipated in late August
CLVS: 23.40 (-0.19)
Commit To Buy Clovis Oncology At $10, Earn 25.6% Annualized Using Options
StockOptionsChannel.com - Mon Jun 20, 10:38AM CDT
Investors eyeing a purchase of Clovis Oncology Inc stock, but cautious about paying the going market price of $14.17/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract...
CLVS: 23.40 (-0.19)
How These Biotech's Stocks are Performing? - Clovis Oncology, Illumina, NewLink Genetics and Zafgen
PR Newswire - Thu Jun 09, 7:00AM CDT
Some of the biggest opportunities in the equities market are found in tumultuous industries such as Biotechnology. The segment continues to present a number of remarkable trades as well as potentially good investment that are waiting to be discovered. This morning ActiveWallSt.com features these four biotech stocks in its technical alerts service: Clovis Oncology Inc. (NASDAQ: CLVS), Illumina Inc. (NASDAQ: ILMN), NewLink Genetics Corp. (NASDAQ: NLNK), and Zafgen Inc. (NASDAQ: ZFGN). Learn more about these stocks and receive your complimentary trade alerts at:
ZFGN: 2.95 (-0.09), CLVS: 23.40 (-0.19), NLNK: 9.91 (-0.40), ILMN: 167.90 (-0.66)
Clovis Oncology Presents Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer and Pancreatic Cancer at 2016 ASCO Annual Meeting
BusinessWire - Mon Jun 06, 7:30AM CDT
Clovis Oncology (NASDAQ:CLVS) announced updated phase 2 results from Part 1 of the ongoing ARIEL2 study in patients with advanced ovarian cancer as well as the final results of the RUCAPANC study of rucaparib in pancreatic cancer at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Rucaparib is the Company's oral, potent, small molecule inhibitor of PARP1, PARP2 and PARP3 currently being developed for the treatment of ovarian cancer, specifically in patients with tumors with BRCA mutations and other DNA repair deficiencies beyond BRCA, including those with high genomic loss of heterozygosity (LOH) also known as "BRCA-like."
CLVS: 23.40 (-0.19)
Clovis Oncology Announces Data Presentations at 2016 ASCO Annual Meeting
BusinessWire - Thu May 19, 3:40PM CDT
--Rolling New Drug Application (NDA) submission for rucaparib for the treatment of patients with advanced ovarian cancer expected to complete during Q2 2016
CLVS: 23.40 (-0.19)
The Shuman Law Firm Investigates Clovis Oncology, Inc.
BusinessWire - Wed May 11, 12:38PM CDT
The Shuman Law Firm announces that it is investigating potential claims against certain officers and directors of Clovis Oncology, Inc. ("Clovis" or the "Company"
(Nasdaq: CLVS). Clovis is a Boulder, CO-based biopharmaceutical company that focuses on anti-cancer agents. CLVS: 23.40 (-0.19)
Clovis reports 1Q loss
Automated Insights - Thu May 05, 4:48PM CDT
BOULDER, Colo. (AP) _ Clovis Oncology Inc. (CLVS) on Thursday reported a loss of $83.4 million in its first quarter.
CLVS: 23.40 (-0.19)
Clovis Oncology to Announce First Quarter 2016 Financial Results and Host Webcast Conference Call on May 5
BusinessWire - Tue Apr 26, 7:00AM CDT
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2016 financial results on Thursday, May 5, 2016, after the close of the U.S. financial markets. Clovis' senior management will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the company's results in greater detail.
CLVS: 23.40 (-0.19)
Market Exclusive Research Weekly Biotech Report
ACCESSWIRE - Mon Apr 18, 8:27AM CDT
NEW YORK, NY / ACCESSWIRE / April 18, 2016 / The week just gone gave us plenty to talk about in the biotech space, with two significant developments - one in oncology and one in a rare genetic growth disorder called acromegaly. Here's what happened, and how things played out as a result.
PGNX: 5.96 (-0.18), CLVS: 23.40 (-0.19), SRPT: 26.89 (+0.33), COLL: 8.98 (+0.15), CHMA: 2.51 (+0.05)
The Zacks Analyst Blog Highlights: Intercept, Clovis, AbbVie, Relypsa and Horizon Pharma
Zacks Equity Research - Zacks Investment Research - Thu Apr 14, 8:30AM CDT
The Zacks Analyst Blog Highlights: Intercept, Clovis, AbbVie, Relypsa and Horizon Pharma
CLVS: 23.40 (-0.19), RLYP: 31.98 (-0.01), HZNP: 17.84 (-0.78), ICPT: 150.74 (+3.92), ABBV: 64.12 (+0.09)
Biotech Stock Roundup: FDA Advisory Panels Say Yes to Intercept, No to Clovis
Arpita Dutt - Zacks Investment Research - Wed Apr 13, 9:02AM CDT
A couple of experimental drugs were reviewed by the FDA's advisory panels with a positive outcome for Intercept (ICPT) while Clovis (CLVS) faces a possible delay in gaining approval for its drug.
VRTX: 95.11 (+0.36), CLVS: 23.40 (-0.19), RLYP: 31.98 (-0.01), HZNP: 17.84 (-0.78), ALXN: 123.67 (-1.96), ICPT: 150.74 (+3.92), ABBV: 64.12 (+0.09)
Why Horizon Pharma, Och-Ziff Capital Management, and Clovis Oncology Slumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Tue Apr 12, 5:58PM CDT
Image: Och-Ziff. Tuesday was a strong day for the stock market, and the primary reason was positive movement in the energy markets. Crude oil prices rose almost $2 per barrel, moving above $42 and carrying a huge swath of energy stocks along with...
CLVS: 23.40 (-0.19), HZNP: 17.84 (-0.78), OZM: 3.87 (+0.04)
Clovis Oncology's Failure Is a Big Win for AstraZeneca
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 12, 5:41PM CDT
IMAGE SOURCE: FLICKR USER STOCKMONKEYS.COM. Following a disastrous drubbing by the Food and Drug Administration's key advisory committee, the future for Clovis Oncology 's once-promising non-small cell lung cancer drug rociletinib is up in the...
CLVS: 23.40 (-0.19), AZN: 33.31 (+0.71)
Clovis Oncology Provides Update on FDA Oncologic Drugs Advisory Committee Meeting to Review Rociletinib for Treatment of Advanced T790M-Positive Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer
BusinessWire - Tue Apr 12, 12:52PM CDT
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) met to discuss approval of the New Drug Application (NDA) for rociletinib, an investigational therapy for the treatment of patients with mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC) who have been previously treated with an EGFR-targeted therapy and have the T790M mutation.
CLVS: 23.40 (-0.19)
Trading of Clovis Oncology, Inc. Common Stock Halted
BusinessWire - Tue Apr 12, 6:04AM CDT
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that NASDAQ has halted trading of the Company's common stock. The U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) is meeting this morning to discuss the company's New Drug Application (NDA) for rociletinib for the treatment of patients with mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC) who have been previously treated with an EGFR-targeted therapy and have the EGFR T790M mutation.
CLVS: 23.40 (-0.19)
(0)
(0)Scroll down for more posts ▼